Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research focused on Cancer research and Lymphangiogenesis, with related work in Immune system, Metastasis, Exemestane. Notable publications include 'Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer', 'Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial', and 'Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial'.
Safety and efficacy of QLS31905 in patients with advanced solid tumors: Updated data from phase 1 study.
Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, <i>EGFR</i> ‐mutated, advanced non‐small cell lung cancer: data from a randomized phase III trial (AENEAS)
Tumor-immune microenvironment and NRF2 associate with clinical efficacy of PD-1 blockade combined with chemotherapy in lung squamous cell carcinoma
Abstract 5462: Elevated creatine phosphokinase (CPK) as a strong predictor of aumolertinib (Au) treatment response in patients (pts) with advanced non-small cell lung cancer (NSCLC): post-hoc analysis of AENEAS
Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer
Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial
Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study
ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation
Tumor-derived ILT4 induces T cell senescence and suppresses tumor immunity
Efficacy, Safety, and Immunogenicity of HLX04Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatmentfor Metastatic Colorectal Cancer: Results of a Randomized, Double-Blind Phase IIIStudy
SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-β, for advanced NSCLC with <i>EGFR</i> mutations: Data from a multicenter phase 1 study.
RATIONALE-307: Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous NSCLC in patients aged ≥ 65.
ILT3 promotes tumor cell motility and angiogenesis in non-small cell lung cancer
A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer – The FALUCA study
Phase III study of tislelizumab plus chemotherapy vs chemotherapy alone as first-line (1L) treatment for advanced squamous non-small cell lung cancer (sq NSCLC).
Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial
The prognostic landscape of tumor-infiltrating immune cells in cervical cancer
[A multicenter, randomized, controlled, phase Ⅲ clinical study of PEG-rhG-CSF for preventing chemotherapy-induced neutropenia in patients with breast cancer and non-small cell lung cancer].
Molecular mechanism underlying the tumor-promoting functions of carcinoma-associated fibroblasts
Using chemo-drugs or irradiation to break immune tolerance and facilitate immunotherapy in solid cancer
TNFR1 mediates TNF-α-induced tumour lymphangiogenesis and metastasis by modulating VEGF-C-VEGFR3 signalling
Novel Mechanism of Macrophage-Mediated Metastasis Revealed in a Zebrafish Model of Tumor Development
Construction and evaluation of a novel humanized HER2-specific chimeric receptor
Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis